MUNICH— A doubling of progression free survival (PFS) and objective response rate (ORR) was observed in patients who had their previously untreated advanced renal cell cancer (RCC) treated with a combination of the vascular endothelial growth factor (VEGF) inhibitor axitinib plus the anti-programmed death one ligand (PD-L1) avelumab in comparison with those receiving standard sunitinib anti-VEGF therapy in the randomized phase threeJAVELIN Renal 101 clinical trial. Findings were reported at the 2018 annual congress of the European Society for Medical Oncology (ESMO). http://212.114.167.162/slidecenter/esmo2018/attendee/confcal/session/calendar?q=LBA6_PR
Robust PFS
“The progression free survival was so robust, the objective response rate was robust [and] the safety profile was favorable that [this] warrants this combination as a new standard of care in patients with advanced kidney cancer,” lead investigator of the study Robert J Motzer MD PhD, a medical oncologist at Memorial Sloan-Kettering Cancer Center in New York told the Audio Journal of Oncology.
